MedTech Business - February 3, 2026
ADDvise has applied for delisting from Nasdaq First North
On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.
Acquisition - February 3, 2026
Nanologica acquires Nordic CDMO
Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.
Biotech Business - January 13, 2026
Evaxion expands AI-Immunology platform into autoimmune diseases
Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
Denmark - December 15, 2025
Japanese quantum startup choses Copenhagen for European headquarters
The Japanese start-up QunaSys has chose to locate their European headquarters in Innovation District Copenhagen, in the start-up community Quantum Denmark.
MedTech Business - December 9, 2025
CellaVision receives CE marking
CellaVision has announced that its new CellaVision Bone Marrow Aspirate (BMA) Application has received CE marking approval as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR).
Agreement - December 8, 2025
OssDsign signs new agreement with IDN in the US
The company has signed an agreement with an IDN (Integrated Delivery Network) in the Western US, marking the company’s most significant opportunity for sales growth in the region to date it states.
